High citrate dialysate and uses thereof

Details High citrate dialysate and uses thereof High citrate dialysate and uses thereof

2011-01-04

2011-01-04

Hand, Melanie J (Department: 3761)

Surgery

Blood drawn and replaced or treated and returned to body

Constituent removed from blood and remainder returned to body

C604S004010, C210S645000, C210S646000

Reexamination Certificate

active

07862530

ABSTRACT:
The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.19 to 1.34±0.2 (p=0.01). This increased urea clearance may be the result of the anticoagulant property of citrate maintaining patency of the dialyzer membrane. The increase in pre-dialysis serum HCO3may represent increased delivery from the dialysate and production from citric acid.

REFERENCES:
patent: 3962075 (1976-06-01), Fialkoff et al.
patent: 4339433 (1982-07-01), Kartinos et al.
patent: 4451454 (1984-05-01), Wong
patent: 4500309 (1985-02-01), Diederich et al.
patent: 4581141 (1986-04-01), Ash
patent: 4661246 (1987-04-01), Ash
patent: 4663166 (1987-05-01), Veech
patent: 4756838 (1988-07-01), Veltman
patent: 4784495 (1988-11-01), Jonsson et al.
patent: 4879280 (1989-11-01), Seyffart et al.
patent: 4886789 (1989-12-01), Milner
patent: 4906616 (1990-03-01), Gilchrist et al.
patent: 4938873 (1990-07-01), Rossi
patent: 5032615 (1991-07-01), Ward et al.
patent: 5108767 (1992-04-01), Mulchandani et al.
patent: 5252213 (1993-10-01), Ahmad et al.
patent: 5474992 (1995-12-01), Ogata et al.
patent: 5589197 (1996-12-01), Shockley et al.
patent: 5591344 (1997-01-01), Kenley et al.
patent: 5624668 (1997-04-01), Lawrence et al.
patent: 5645734 (1997-07-01), Kenley et al.
patent: 5651893 (1997-07-01), Kenley et al.
patent: 5658456 (1997-08-01), Kenley et al.
patent: 5674390 (1997-10-01), Matthews et al.
patent: 5674404 (1997-10-01), Kenley et al.
patent: 5690821 (1997-11-01), Kenley et al.
patent: 5698100 (1997-12-01), Levin et al.
patent: 5728678 (1998-03-01), Trimbo et al.
patent: 5762782 (1998-06-01), Kenley et al.
patent: 5780438 (1998-07-01), Gilchrist et al.
patent: 5783072 (1998-07-01), Kenley et al.
patent: 5827820 (1998-10-01), duMoulin et al.
patent: 5851483 (1998-12-01), Nicolle et al.
patent: 5906978 (1999-05-01), Ash
patent: 5945129 (1999-08-01), Knerr et al.
patent: 6019925 (2000-02-01), Diamantoglou et al.
patent: 6077836 (2000-06-01), Milner
patent: 6610206 (2003-08-01), Callan et al.
patent: 6779468 (2004-08-01), Gupta
patent: 2004/0060865 (2004-04-01), Callan et al.
patent: 41 14 908 (1992-11-01), None
patent: 196 54 746 (1998-07-01), None
patent: 0 022 922 (1981-01-01), None
patent: 457 960 (1991-11-01), None
patent: 0 564 672 (1993-10-01), None
patent: 821 951 (1998-02-01), None
patent: 1 059 083 (2000-12-01), None
patent: 8-92070 (1996-04-01), None
patent: 10-87478 (1998-04-01), None
patent: WO 92/11046 (1992-07-01), None
patent: WO 9211046 (1992-07-01), None
patent: WO 96/01118 (1996-01-01), None
patent: WO 98/06482 (1998-02-01), None
patent: WO 98/29151 (1998-07-01), None
patent: WO 98/29434 (1998-07-01), None
patent: WO 99/07419 (1999-02-01), None
Abstract of DE 196 54 746, Jul. 2, 1998, esp@cenet database.
Abstract of DE 41 14 908, Nov. 12, 1992, esp@cenet database.
J. Van Der Meulen et al., “Citrate anticoagulation and dialysate with reduced buffer content in chronic hemodialysis,”Clinical Nephrology37(1): 36-41, 1992.
Morishita Roussel KK, “Agent for blood dialysis—comprises electrolytes contg. sodium, calcium, chloride and hydrogen-carbonate ions,”Derwent World Patent Index, Accession No. 235949, 1996. Abstract for JP 8-092070.
Ahmad et al., “Increased Dialyzer Efficiency Using a Dialysate Containing Citric Acid in Place of Acetic Acid,”J. Am. Soc. Nephrol. 10: 188A, Abstract A0961, 1999.
Ahmad et al., “Effect of the Normalization of Acid-Base Balance on Postdialysis Plasma Bicarbonate,”Trans. Am. Soc. Artif. Intern. Organs26: 318-321, 1980.
Apsner et al., “A Simple Method for Citrate Anticoagulation (CA) during High Flux Dialysis: Experience with 760 Dialyses in 34 Patients,”J. Am. Soc. Nephrol. 10: 188A, Abstract A0962, 1999.
Brady and Hasbargen, “Correction of Metabolic Acidosis and Its Effect on Albumin in Chronic Hemodialysis Patients,”Am. J. Kid. Dis. 31(1): 35-40, Jan. 1998.
Drukker et al.,Replacement of Renal Function by Dialysis, Fourth Edition, Kluwer Academic Publishers, Dordrecht, The Netherlands, 1996, p. 345.
Dzik and Kirkley, “Citrate Toxicity During Massive Blood Transfusion,”Transfusion Medicine Reviews2(2): 76-94, Jun. 1988.
European Pharmacopoeia Commission, “Peritoneal Dialysis, Solutions For,” inEuropean Pharmacopoeia, 3rdedition, Strasbourg, Germany, Council of Europe, 1997, pp. 1301-1303.
Golberg, “Pharmacology of Parenteral Iron Preparations,” in Wallerstein and Mettier (eds.),Iron in Clinical Medicine, University of California Press, Berkeley and Los Angeles, 1958, pp. 74-92.
Guest et al., “Functional consequences of correction of metabolic acidosis in hemodialysis patients,”J. Am. Soc. Nephrol. 8: 236A, Abstract No. A1090, Sep. 1997.
Jander and Blasius,Lehrbuch der analytischen and präparativen anorganischen Chemie(translatedText book of analytical and preparative inorganic chemistry), S. Hirzel Verlag Stuttgart, Germany, 1973, 10th, revised edition, Chapter 2.6.5.5.4, “Buffer Capacity,” p. 66, translation.
Lin et al., “Influence of Rapid Correction of Metabolic Acidosis on Serum Osteocalcin Level in Chronic Renal Failure,”Asaio Journal40: M440-M444, 1994.
Reaich et al., “Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation,”Am. J. Physio. 7: E230-E235, 1993.
Sonikian et al., “Potential Effect of Metabolic Acidosis on β2—Microglobulin Generation: in Vivo and in Vitro Studies,”J. Am.Soc. Nephrol. 7(2): 350-356, 1996.
Suh and Wadhwa, “Iron Dextran Treatment in Peritoneal Dialysis Patients on Erythropoietin,”Adv. Perit. Dial. 8: 464-466, 1992.
Wu et al., “Clinical application of EPO and chalybeate,”Journal of Postgraduates of Medicine24(4): 50-52, Apr. 2001, with English translation.
Yu et al., “Discussion on application of zinc-containing dialysate in hemodialysis patients,”Chinese Journal of Renal Diseases11(5): 281, Oct. 1995, with English translation.
Caruana and Keep, “Anticoagulation,” in John T. Daugirdas, M.D. and Todd S. Ing, M.D. (eds.),Handbook of Dialysis, Little, Brown and Company, 1994, pp. 121-135.
Flanigan et al., “Regional Hemodialysis Anticoagulation: Hypertonic Tri-Sodium Citrate or Anticoagulant Citrate Dextrose-A,”American Journal of Kidney Diseases27(4): 519-524, Apr. 1996.
Kossmann et al., 55% Heparin Reduction Using Citrate Dialysate (Citrasate®), http://www.dialmedsupply.com/citrasate/PDF/HeparinReduction.pdf, download date Nov. 24, 2009.
Perdrix et al., “Anticoagulation régionale par le citrate au cours de l'hémodialyse chez les patients á haut risque hémorragique,”Ann. Fr. Anesth. Réanim. 7: 31-35, 1988.
Pinnick et al., “Regional Citrate Anticoagulation for Hemodialysis in the Patient at High Risk for Bleeding,”The New England Journal of Medicine308(5): 258-261, Feb. 3, 1983.
{hacek over (S)}rámek et al., “Continuous venovenous hemodiafiltration (CVVHDF) with citrate anticoagulation in the tr

Affiliated with

Also associated with

Rating

High citrate dialysate and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High citrate dialysate and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High citrate dialysate and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2723580